Search
Zirconium panitumumab Zr-89
go.drugbank.com/drugs/DB19228InvestigationalZirconium panitumumab Zr-89 is under investigation in clinical trial NCT05423197 (Study Evaluating Zr-panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in Head and Neck Squamous
Adermastat
go.drugbank.com/drugs/DB28906InvestigationalAdermastat is under investigation in clinical trial NCT03858686 (The Effect of FP-025, on Allergen-induced Airway Responses in Mild Eosinophilic House Dust Mite (HDM)-Allergic Asthma.).
Levosalbutamol
go.drugbank.com/drugs/DB13139ApprovedLevosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Salbutamol has been marketed as a racemic mixture, although beta2-agonist...
Liothyronine
go.drugbank.com/drugs/DB00279ApprovedInvestigationalVet approvedLiothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine w...
Navitoclax
go.drugbank.com/drugs/DB12340InvestigationalNavitoclax has been used in trials studying the treatment and basic science of Solid Tumors, Non-Hodgkin's Lymphoma, EGFR Activating Mutation, Chronic Lymphoid Leukemia, and Hematological Malignancies,
Dioxybenzone
go.drugbank.com/drugs/DB11221ApprovedWithdrawnDioxybenzone, or benzophenone-8, is an organic compound derived from DB01878 that is used as a sunscreen agent. It absorbed UV-B and UV-AII rays. Dioxybenzone is an approved sunscreen ingredient in concentrations up to 3% .
Pegzilarginase
go.drugbank.com/drugs/DB14780ApprovedPegzilarginase is a recombinant, cobalt-substituted, and pegylated human arginase 1 enzyme therapy designed to address the underlying metabolic deficit in arginase 1 deficiency (ARG1-D). By substituting the native manganese cofactor with...
Urelumab
go.drugbank.com/drugs/DB12077InvestigationalUrelumab has been used in trials studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, and Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma.
EMZ702
go.drugbank.com/drugs/DB05021InvestigationalEMZ702, a non-toxic agent that has strong anti-viral synergy with interferon, is an ideal candidate for combination with current standard hepatitis C treatments.
1-Deoxy-D-xylulose 5-phosphate
go.drugbank.com/drugs/DB02496Experimentalproteins that 1-Deoxy-D-xylulose 5-phosphate targets include 1-Deoxy-D-xylulose 5-phosphate reductoisomerase and pyridoxine 5'-phosphate synthase. 1-Deoxy-D-xylulose 5-phosphate is an intermediate in the non-mevalonate